Incidence of infections in patients with giant cell arteritis: A cohort study

Arthritis Care and Research

Volumn 64, Issue 4, 2012, Pages 581-588

  Durand, Madeleine ^a   Thomas, Sara L ^b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; COHORT ANALYSIS; FEMALE; FOLLOW UP; GIANT CELL ARTERITIS; HUMAN; INCIDENCE; INFECTION; INFECTION RISK; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; SEPSIS; URINARY TRACT INFECTION;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GIANT CELL ARTERITIS; GREAT BRITAIN; HUMANS; INCIDENCE; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RESPIRATORY TRACT INFECTIONS; RISK FACTORS; SEPSIS; STEROIDS; URINARY TRACT INFECTIONS;

EID: 84859757965     PISSN: 00043591     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21569     Document Type: Article

References (34)

1. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, Miranda-Filloy J, Gonzalez-Juanatey C, Martin J, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 2009;61:1454-61.
2. Kawasaki A, Purvin V. Giant cell arteritis: an updated review. Acta Ophthalmol 2009;87:13-32.
3. Haugeberg G, Paulsen PQ, Bie RB. Temporal arteritis in Vest Agder County in southern Norway: incidence and clinical findings. J Rheumatol 2000;27:2624-7.
4. Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, Gross WL. Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum 2005;53:93-9. (Pubitemid 40216357)
5. Pamuk ON, Donmez S, Karahan B, Pamuk GE, Cakir N. Giant cell arteritis and polymyalgia rheumatica in northwestern Turkey: clinical features and epidemiological data. Clin Exp Rheumatol 2009;27:830-3.
6. Tam S, Wong TC. Temporal arteritis in Hong Kong. Int J Rheum Dis 2008;11:163-9. (Pubitemid 352044375)
7. Wang X, Hu ZP, Lu W, Tang XQ, Yang HP, Zeng LW, et al. Giant cell arteritis. Rheumatol Int 2008;29:1-7.
8. Le Page L, Duhaut P, Seydoux D, Bosshard S, Ecochard R, Abbas F, et al. Incidence of cardiovascular events in giant cell arteritis: preliminary results of a prospective double cohort study (GRACG). Rev Med Intern 2006;27:98-105. In French. (Pubitemid 43188739)
9. Ray JG, Mamdani MM, Geerts WH. Giant cell arteritis and cardiovascular disease in older adults. Heart 2005;91:324-8. (Pubitemid 40299211)
10. Gonzalez-Gay MA, Rubiera G, Pineiro A, Garcia-Porrua C, Pego-Reigosa R, Gonzalez-Juanatey C, et al. Ischemic heart disease in patients from Northwest Spain with biopsy proven giant cell arteritis: a population-based study. J Rheumatol 2005;32:502-6. (Pubitemid 40381422)
11. Uddhammar A, Eriksson AL, Nystrom L, Stenling R, Rantapaa-Dahlqvist S. Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. J Rheumatol 2002;29:737-42. (Pubitemid 34308459)
12. Proven A, Gabriel SE, Orces C, O'Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003;49:703-8. (Pubitemid 37296477)
13. Khalifa M, Karmani M, Jaafoura NG, Kaabia N, Letaief AO, Bahri F. Epidemiological and clinical features of giant cell arteritis in Tunisia. Eur J Int Med 2009;20:208-12.
14. Chevalet P, Barrier JH, Glemarec J, el Kouri D, Hamidou M, de Wazieres B, et al. Horton's disease in elderly patients aged over 75: clinical course, complications of corticotherapy. Comparative study of 164 patients towards a reduced initial dose. Rev Med Interne 2001;22:624-30. In French. (Pubitemid 32679086)
15. Huston KA, Hunder GG, Lie JT, Kennedy RH, Elveback LR. Temporal arteritis: a 25-year epidemiologic, clinical, and pathologic study. Ann Intern Med 1978;88:162-7. (Pubitemid 8282146)
16. Hachulla E, Boivin V, Pasturel-Michon U, Fauchais AL, Bouroz-Joly J, Perez-Cousin M, et al. Prognostic factors and longterm evolution in a cohort of 133 patients with giant cell arteritis. Clin Exp Rheumatol 2001;19:171-6. (Pubitemid 32372453)
17. National Institutes of Health. 2008. URL: http://clinicaltrials.gov/ct2/ home.
18. Beyer C, Axmann R, Sahinbegovic E, Distler JH, Manger B, Schett G, et al. Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis [abstract]. Ann Rheum Dis 2011;70:1874-5.
19. Seitz M, Reichenbach S, Bonel HM, Adler S, Wermelinger F, Villiger PM. Rapid induction of remission in large vessel vasculitis by IL-6 blockade: a case series. Swiss Med Wkly 2011;141:w13156.
20. Klein NC, Go CH, Cunha BA. Infections associated with steroid use. Infect Dis Clin North Am 2001;15:423-32, viii. (Pubitemid 32606908)
21. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989;11:954-63.
22. Chevalet P, Barrier JH, Pottier P, Magadur-Joly G, Pottier MA, Hamidou M, et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol 2000;27:1484-91. (Pubitemid 30354049)
23. Mahr AD, Jover JA, Spiera RF, Hernandez-Garcia C, Fernandez-Gutierrez B, Lavalley MP, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007;56:2789-97. (Pubitemid 47237299)
24. Schafer VS, Kermani TA, Crowson CS, Hunder GG, Gabriel SE, Ytterberg SR, et al. Incidence of herpes zoster in patients with giant cell arteritis: a population-based cohort study. Rheumatology (Oxford) 2010;49:2104-8.
25. The Health Improvement Network. EPIC, 2008. URL: http://www.thin-uk.com/.
26. Blak BT, Thompson M, Bourke A. National representativeness and data quality of the Health Improvement Network (THIN) database of primary care information for epidemiological research [abstract]. 9th Annual Conference of the UK Federation of Primary Care Research Organisations. Podium presentation. Liverpool, UK; 2006.
27. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007;16:393-401. (Pubitemid 46656860)
28. Lewis JD, Bilker WB, Weinstein R, Strom BL. The relationship between time since registration and measured incidence rates in the General Practice Research Database. Pharmacoepidemiol Drug Saf 2005;14:443-51. (Pubitemid 40990739)
29. Smeeth L, Cook C, Hall AJ. Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990-2001. Ann Rheum Dis 2006;65:1093-8. (Pubitemid 44133274)
30. Bahlas S, Ramos-Remus C, Davis P. Clinical outcome of 149 patients with polymyalgia rheumatica and giant cell arteritis. J Rheumatol 1998;25:99-104. (Pubitemid 28060126)
31. Genereau T, Cabane J. Benefits of corticosteroids in the treatment of temporal arteritis and polymyalgia rheumatica: advantages and disadvantages. A meta-analysis. Rev Med Intern 1992;13:387-91. In French. (Pubitemid 23010988)
32. Nesher G, Sonnenblick M, Friedlander Y. Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients. J Rheumatol 1994;21:1283-6. (Pubitemid 24234666)
33. Schmidt WA, Moll A, Seifert A, Schicke B, Gromnica-Ihle E, Krause A. Prognosis of large-vessel giant cell arteritis. Rheumatology (Oxford) 2008;47:1406-8.
34. Smith SA, Poland GA. Influenza and pneumococcal immunization in diabetes. Diabetes Care 2004;27 Suppl 1:S111-3.